Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Pipeline Developments & Deals by Foundation for Angelman Syndrome Therapeutics

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Foundation for Angelman Syndrome Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Biofit 2020

              Participation Not Confirmed

              Update your events

              The Foundation for Angelman Syndrome Therapeutics and Lixte Biotechnology Collaborate to Support the Preclinical Study of LB-100

              Contact the Supplier

              Lead Product(s): LB-100

              Therapeutic Area: Genetic Disease Product Name: LB-100

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lixte Biotechnology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 18, 2020

              Details:

              Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).

              PharmaCompass__DigitalAd